Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 126

1.

Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus.

Stray K, Perron M, Porter DP, Anderson F, Lewis SA, Perry J, Miller M, Cihlar T, DeVincenzo J, Chien JW, Jordan R.

J Infect Dis. 2020 Jan 23. pii: jiaa028. doi: 10.1093/infdis/jiaa028. [Epub ahead of print]

PMID:
31971597
2.

A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.

DeVincenzo J, Tait D, Efthimiou J, Mori J, Kim YI, Thomas E, Wilson L, Harland R, Mathews N, Cockerill S, Powell K, Littler E.

Antimicrob Agents Chemother. 2020 Jan 27;64(2). pii: e01884-19. doi: 10.1128/AAC.01884-19. Print 2020 Jan 27.

3.

Respiratory Syncytial Virus Disease Severity Is Associated with Distinct CD8+ T-Cell Profiles.

Siefker DT, Vu L, You D, McBride A, Taylor R, Jones TL, DeVincenzo J, Cormier SA.

Am J Respir Crit Care Med. 2020 Feb 1;201(3):325-334. doi: 10.1164/rccm.201903-0588OC.

PMID:
31644878
4.

Elevated Levels of Type 2 Respiratory Innate Lymphoid Cells in Human Infants with Severe Respiratory Syncytial Virus Bronchiolitis.

Vu LD, Siefker D, Jones TL, You D, Taylor R, DeVincenzo J, Cormier SA.

Am J Respir Crit Care Med. 2019 Dec 1;200(11):1414-1423. doi: 10.1164/rccm.201812-2366OC.

PMID:
31237777
5.

SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, DeVincenzo JP, Simões EAF, Krilov LR, Forbes ML, Pannaraj PS, Espinosa CM, Welliver RC, Wolkoff LI, Yogev R, Checchia PA, Domachowske JB, Halasa N, McBride SJ, Kumar VR, McLaurin KK, Rizzo CP, Ambrose CS.

Am J Perinatol. 2019 Apr 16. doi: 10.1055/s-0039-1681014. [Epub ahead of print]

6.

Uncovering critical properties of the human respiratory syncytial virus by combining in vitro assays and in silico analyses.

Beauchemin CAA, Kim YI, Yu Q, Ciaramella G, DeVincenzo JP.

PLoS One. 2019 Apr 15;14(4):e0214708. doi: 10.1371/journal.pone.0214708. eCollection 2019.

7.

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.

Patel K, Kirkpatrick CM, Nieforth KA, Chanda S, Zhang Q, McClure M, Fry J, Symons JA, Blatt LM, Beigelman L, DeVincenzo JP, Huntjens DR, Smith PF.

J Antimicrob Chemother. 2019 Feb 1;74(2):442-452. doi: 10.1093/jac/dky415.

PMID:
30376079
8.

Comparing molecular quantification of herpes simplex virus (HSV) in cerebrospinal fluid (CSF) with quantitative structural and functional disease severity in patients with HSV encephalitis (HSVE): Implications for improved therapeutic approaches.

Ramirez KA, Choudhri AF, Patel A, Lenny NT, Thompson RE, Berkelhammer Greenberg L, Clanton Watson N, Kocak M, DeVincenzo JP.

J Clin Virol. 2018 Oct;107:29-37. doi: 10.1016/j.jcv.2018.08.005. Epub 2018 Aug 18.

PMID:
30170224
9.

Comparison of antiviral resistance across acute and chronic viral infections.

Mason S, Devincenzo JP, Toovey S, Wu JZ, Whitley RJ.

Antiviral Res. 2018 Oct;158:103-112. doi: 10.1016/j.antiviral.2018.07.020. Epub 2018 Aug 4. Review.

PMID:
30086337
10.

Rat Lungworm Infection Associated with Central Nervous System Disease - Eight U.S. States, January 2011-January 2017.

Liu EW, Schwartz BS, Hysmith ND, DeVincenzo JP, Larson DT, Maves RC, Palazzi DL, Meyer C, Custodio HT, Braza MM, Al Hammoud R, Rao S, Qvarnstrom Y, Yabsley MJ, Bradbury RS, Montgomery SP.

MMWR Morb Mortal Wkly Rep. 2018 Aug 3;67(30):825-828. doi: 10.15585/mmwr.mm6730a4.

11.

Use of real-time semiquantitative PCR data in management of a neonatal intensive care unit adenovirus outbreak.

Hysmith ND, Tanner MR, Arnold SR, Buckingham SC, Patel AR, Dhanireddy R, Comeaux K, Joyner J, Hoehn ME, DeVincenzo JP.

Infect Control Hosp Epidemiol. 2018 Sep;39(9):1074-1079. doi: 10.1017/ice.2018.162. Epub 2018 Jul 18.

PMID:
30019659
12.

Unrecognized prolonged viral replication in the pathogenesis of human RSV infection.

Bagga B, Harrison L, Roddam P, DeVincenzo JP.

J Clin Virol. 2018 Sep;106:1-6. doi: 10.1016/j.jcv.2018.06.014. Epub 2018 Jun 27.

PMID:
30007135
13.

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study.

Stevens M, Rusch S, DeVincenzo J, Kim YI, Harrison L, Meals EA, Boyers A, Fok-Seang J, Huntjens D, Lounis N, Mari N K, Remmerie B, Roymans D, Koul A, Verloes R.

J Infect Dis. 2018 Jul 24;218(5):748-756. doi: 10.1093/infdis/jiy227.

PMID:
29684148
14.

Do asymptomatic respiratory viral infections occur?

Tomlinson RH, Harrison LG, Meals EA, DeVincenzo JP.

J Clin Virol. 2018 May;102:93-94. doi: 10.1016/j.jcv.2018.03.002. Epub 2018 Mar 5. No abstract available.

PMID:
29529485
15.

The antiviral effects of RSV fusion inhibitor, MDT-637, on clinical isolates, vs its achievable concentrations in the human respiratory tract and comparison to ribavirin.

Kim YI, Pareek R, Murphy R, Harrison L, Farrell E, Cook R, DeVincenzo J.

Influenza Other Respir Viruses. 2017 Nov;11(6):525-530. doi: 10.1111/irv.12503. Epub 2017 Oct 30.

16.

Angiostrongylus cantonensis Eosinophilic Meningitis in an Infant, Tennessee, USA.

Flerlage T, Qvarnstrom Y, Noh J, Devincenzo JP, Madni A, Bagga B, Hysmith ND.

Emerg Infect Dis. 2017 Oct;23(10):1756-1758. doi: 10.3201/eid2310.170978.

17.

Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.

Kim L, Rha B, Abramson JS, Anderson LJ, Byington CL, Chen GL, DeVincenzo J, Edwards KM, Englund JA, Falsey AR, Griffin MR, Karron RA, Martin KG, Meissner HC, Munoz FM, Pavia AT, Piedra PA, Schaffner W, Simões EAF, Singleton R, Talbot HK, Walsh EE, Zucker JR, Gerber SI.

Clin Infect Dis. 2017 Sep 15;65(6):1020-1025. doi: 10.1093/cid/cix432.

18.

Deep sequencing of RSV from an adult challenge study and from naturally infected infants reveals heterogeneous diversification dynamics.

Lau JW, Kim YI, Murphy R, Newman R, Yang X, Zody M, DeVincenzo J, Grad YH.

Virology. 2017 Oct;510:289-296. doi: 10.1016/j.virol.2017.07.017. Epub 2017 Aug 3.

19.

Prolonged viral replication and longitudinal viral dynamic differences among respiratory syncytial virus infected infants.

Brint ME, Hughes JM, Shah A, Miller CR, Harrison LG, Meals EA, Blanch J, Thompson CR, Cormier SA, DeVincenzo JP.

Pediatr Res. 2017 Nov;82(5):872-880. doi: 10.1038/pr.2017.173. Epub 2017 Aug 9.

20.

SNP-mediated disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe influenza in humans.

Allen EK, Randolph AG, Bhangale T, Dogra P, Ohlson M, Oshansky CM, Zamora AE, Shannon JP, Finkelstein D, Dressen A, DeVincenzo J, Caniza M, Youngblood B, Rosenberger CM, Thomas PG.

Nat Med. 2017 Aug;23(8):975-983. doi: 10.1038/nm.4370. Epub 2017 Jul 17.

21.

Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.

Coates M, Brookes D, Kim YI, Allen H, Fordyce EAF, Meals EA, Colley T, Ciana CL, Parra GF, Sherbukhin V, Stockwell JA, Thomas JC, Hunt SF, Anderson-Dring L, Onions ST, Cass L, Murray PJ, Ito K, Strong P, DeVincenzo JP, Rapeport G.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00737-17. doi: 10.1128/AAC.00737-17. Print 2017 Sep.

22.

A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores.

Korell J, Green B, DeVincenzo J, Huntjens D.

Eur J Pharm Sci. 2017 Nov 15;109S:S154-S160. doi: 10.1016/j.ejps.2017.05.070. Epub 2017 Jun 9.

PMID:
28606804
23.

Confounding by Indication Limits Conclusions of Study of Palivizumab Effectiveness.

Boyce TG, Yogev R, DeVincenzo JP, Krilov LR.

Pediatrics. 2017 Mar;139(3). pii: e20164247A. doi: 10.1542/peds.2016-4247A. No abstract available.

24.

Compassionate use experience with high-titer respiratory syncytical virus (RSV) immunoglobulin in RSV-infected immunocompromised persons.

Falsey AR, Koval C, DeVincenzo JP, Walsh EE.

Transpl Infect Dis. 2017 Apr;19(2). doi: 10.1111/tid.12657. Epub 2017 Mar 6.

PMID:
28054734
25.

Vaccination strategies against respiratory syncytial virus.

Yamin D, Jones FK, DeVincenzo JP, Gertler S, Kobiler O, Townsend JP, Galvani AP.

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):13239-13244. Epub 2016 Oct 31.

26.

SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.

Anderson EJ, Krilov LR, DeVincenzo JP, Checchia PA, Halasa N, Simões EA, Domachowske JB, Forbes ML, Pannaraj PS, McBride SJ, McLaurin KK, Kumar VR, Ambrose CS.

Am J Perinatol. 2017 Jan;34(1):51-61. doi: 10.1055/s-0036-1584147. Epub 2016 May 27.

27.

Viral Bronchiolitis in Children.

DeVincenzo JP, Krilov LR, Yogev R.

N Engl J Med. 2016 May 5;374(18):1791. doi: 10.1056/NEJMc1601509. No abstract available.

PMID:
27144865
28.

Respiratory Mucosal Proteome Quantification in Human Influenza Infections.

Marion T, Elbahesh H, Thomas PG, DeVincenzo JP, Webby R, Schughart K.

PLoS One. 2016 Apr 18;11(4):e0153674. doi: 10.1371/journal.pone.0153674. eCollection 2016.

29.

ALS-008176 for Respiratory Syncytial Virus Infection.

DeVincenzo JP, McClure MW, Fry J.

N Engl J Med. 2016 Apr 7;374(14):1391-2. doi: 10.1056/NEJMc1516110. No abstract available.

PMID:
27050226
30.

Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infants.

DeVincenzo JP, Ambrose CS, Makari D, Weiner LB.

Hum Vaccin Immunother. 2016 Apr 2;12(4):971-5. doi: 10.1080/21645515.2015.1115936. Epub 2016 Feb 18.

31.

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.

DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin-Williams R, Smith P, Zhang Q, Beigelman L, Blatt LM, Fry J.

N Engl J Med. 2015 Nov 19;373(21):2048-58. doi: 10.1056/NEJMoa1413275.

32.

Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33.

Saravia J, You D, Shrestha B, Jaligama S, Siefker D, Lee GI, Harding JN, Jones TL, Rovnaghi C, Bagga B, DeVincenzo JP, Cormier SA.

PLoS Pathog. 2015 Oct 16;11(10):e1005217. doi: 10.1371/journal.ppat.1005217. eCollection 2015 Oct.

33.

Viral Specific Factors Contribute to Clinical Respiratory Syncytial Virus Disease Severity Differences in Infants.

Thompson TM, Roddam PL, Harrison LM, Aitken JA, DeVincenzo JP.

Clin Microbiol. 2015 Jun;4(3). pii: 206. Epub 2015 Jun 29.

34.

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.

Gottlieb J, Zamora MR, Hodges T, Musk AW, Sommerwerk U, Dilling D, Arcasoy S, DeVincenzo J, Karsten V, Shah S, Bettencourt BR, Cehelsky J, Nochur S, Gollob J, Vaishnaw A, Simon AR, Glanville AR.

J Heart Lung Transplant. 2016 Feb;35(2):213-21. doi: 10.1016/j.healun.2015.08.012. Epub 2015 Sep 3.

PMID:
26452996
35.

Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children.

Kim YI, Murphy R, Majumdar S, Harrison LG, Aitken J, DeVincenzo JP.

Pediatr Res. 2015 Oct;78(4):380-8. doi: 10.1038/pr.2015.122. Epub 2015 Jun 24.

36.

Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults.

Bagga B, Cehelsky JE, Vaishnaw A, Wilkinson T, Meyers R, Harrison LM, Roddam PL, Walsh EE, DeVincenzo JP.

J Infect Dis. 2015 Dec 1;212(11):1719-25. doi: 10.1093/infdis/jiv281. Epub 2015 May 14.

PMID:
25977264
37.

Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus.

Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, de Haan CA, Wrammert J, Openshaw PJ, Chiu C; Mechanisms of Severe Acute Influenza Consortium Investigators.

Am J Respir Crit Care Med. 2015 May 1;191(9):1040-9. doi: 10.1164/rccm.201412-2256OC.

38.

Challenges and opportunities in developing respiratory syncytial virus therapeutics.

Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE Jr, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ.

J Infect Dis. 2015 Mar 15;211 Suppl 1:S1-S20. doi: 10.1093/infdis/jiu828.

39.

Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus.

Kim YI, DeVincenzo JP, Jones BG, Rudraraju R, Harrison L, Meyers R, Cehelsky J, Alvarez R, Hurwitz JL.

PLoS One. 2014 Nov 21;9(11):e113100. doi: 10.1371/journal.pone.0113100. eCollection 2014.

40.

Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis.

Pickles RJ, DeVincenzo JP.

J Pathol. 2015 Jan;235(2):266-76. doi: 10.1002/path.4462. Review.

41.

Oral GS-5806 activity in a respiratory syncytial virus challenge study.

DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW.

N Engl J Med. 2014 Aug 21;371(8):711-22. doi: 10.1056/NEJMoa1401184.

42.

Limited type I interferons and plasmacytoid dendritic cells during neonatal respiratory syncytial virus infection permit immunopathogenesis upon reinfection.

Cormier SA, Shrestha B, Saravia J, Lee GI, Shen L, DeVincenzo JP, Kim YI, You D.

J Virol. 2014 Aug;88(16):9350-60. doi: 10.1128/JVI.00818-14. Epub 2014 Jun 11.

43.

Multi-center evaluation of the adenovirus R-gene US assay for the detection of adenovirus in respiratory samples.

Manji R, Zheng X, Patel A, Kowerska M, Vossinas M, Drain A, Todd KM, Lenny N, DeVincenzo JP, Ginocchio CC.

J Clin Virol. 2014 Jun;60(2):90-5. doi: 10.1016/j.jcv.2014.03.014. Epub 2014 Mar 29.

PMID:
24768208
44.

Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure.

Grad YH, Newman R, Zody M, Yang X, Murphy R, Qu J, Malboeuf CM, Levin JZ, Lipsitch M, DeVincenzo J.

J Virol. 2014 Jul;88(13):7286-93. doi: 10.1128/JVI.00038-14. Epub 2014 Apr 16.

45.

Sendai virus-based RSV vaccine protects against RSV challenge in an in vivo maternal antibody model.

Jones BG, Sealy RE, Surman SL, Portner A, Russell CJ, Slobod KS, Dormitzer PR, DeVincenzo J, Hurwitz JL.

Vaccine. 2014 May 30;32(26):3264-73. doi: 10.1016/j.vaccine.2014.03.088. Epub 2014 Apr 14.

46.

RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction.

Liesman RM, Buchholz UJ, Luongo CL, Yang L, Proia AD, DeVincenzo JP, Collins PL, Pickles RJ.

J Clin Invest. 2014 May;124(5):2219-33. doi: 10.1172/JCI72948. Epub 2014 Apr 8.

47.

Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus.

Makari D, Checchia PA, Devincenzo J.

Hum Vaccin Immunother. 2014;10(3):607-14. Epub 2013 Dec 6. Review.

48.

Mucosal immune responses predict clinical outcomes during influenza infection independently of age and viral load.

Oshansky CM, Gartland AJ, Wong SS, Jeevan T, Wang D, Roddam PL, Caniza MA, Hertz T, Devincenzo JP, Webby RJ, Thomas PG.

Am J Respir Crit Care Med. 2014 Feb 15;189(4):449-62. doi: 10.1164/rccm.201309-1616OC.

49.

HLA targeting efficiency correlates with human T-cell response magnitude and with mortality from influenza A infection.

Hertz T, Oshansky CM, Roddam PL, DeVincenzo JP, Caniza MA, Jojic N, Mallal S, Phillips E, James I, Halloran ME, Thomas PG, Corey L.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13492-7. doi: 10.1073/pnas.1221555110. Epub 2013 Jul 22.

50.

Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals.

Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, Lambkin-Williams R, Oxford JS, McClain MT, Wilkinson T, Nicholson BP, Ginsburg GS, Devincenzo JP.

Antivir Ther. 2013;18(6):785-91. doi: 10.3851/IMP2629. Epub 2013 May 28.

PMID:
23714753

Supplemental Content

Loading ...
Support Center